You are here

Merck

Bristol Myers adds to neoadjuvant win for Opdivo in lung cancer, escalating early cancer showdown with Merck

Endpoints

Mon, 11/8/21 - 10:58 am

Bristol Myers Squibb

Propel fails to propel Nektar

EP Vantage

Mon, 11/8/21 - 10:48 am

Nektar Therapeutics

bempegaldesleukin

clinical trials

metastatic non-small cell lung cancer

Merck’s Covid-19 antiviral pill receives first authorization in U.K.

Stat

Thu, 11/4/21 - 10:47 am

Merck will support Saudi Arabia effort to build biologics manufacturing operations

Fierce Pharma

Wed, 11/3/21 - 11:36 pm

Merck’s Molnupiravir: When a Private-Public Partnership Bears Fruit

BioSpace

Wed, 11/3/21 - 11:33 pm

Ridgeback Biotherapeutics

Testimony: Elizabeth Holmes Mislead Investors with Use of Schering-Plough Logo

BioSpace

Wed, 11/3/21 - 10:54 am

Elizabeth Holmes

Schering Plough

Merck Delays Acceleron Deal Amidst Continuing Stakeholder Criticism

BioSpace

Mon, 11/1/21 - 11:19 pm

Cytokines claimed spotlight due to COVID-19. Now, Merck will work with Synthekine to understand their role in autoimmune disorders

Fierce Biotech

Mon, 11/1/21 - 10:56 am

drug development

Merck's Keytruda close to becoming top-selling drug in the world

Beckers Hospital Review

Mon, 11/1/21 - 10:39 am

Gilead, Merck to study combination therapy for breast cancer

Pharmaceutical Business Review

Fri, 10/29/21 - 10:56 am

Gilead Sciences

triple negative breast cancer

Go or go go? J&J’s cell therapy heads to the FDA

EP Vantage

Fri, 10/29/21 - 10:33 am

Multiple Myeloma

Merck sees up to $7B in coming sales of coronavirus pill

BioPharma Dive

Thu, 10/28/21 - 10:21 pm

Merck develops new technology to address solubility and speed to market challenges of ADCs

Biopharma Reporter

Thu, 10/28/21 - 10:55 am

drug manufacturing

antibody-drug conjugate

Merck Inks Deal To Share Antiviral Covid Pill With Poorer Countries

Forbes

Wed, 10/27/21 - 10:59 am

Feeling Collaborative, Merck Inks Three More Deals to Strengthen Portfolio

BioSpace

Tue, 10/26/21 - 12:01 am

Xeris Biopharma

Evaxion Biotech

datopotamab deruxtecan

Merck's experimental HIV drug islatravir hits with a PhIII combo win and FDA filing plans

Endpoints

Mon, 10/25/21 - 11:07 am

clinical trials

EMA starts rolling review of Merck's molnupiravir, continuing rapid regulatory response to COVID-19 antiviral data

Fierce Biotech

Mon, 10/25/21 - 10:58 am

Ridgeback Biotherapeutics

Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?

Motley Fool

Sun, 10/24/21 - 10:32 pm

Gilead Sciences

Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?

Motley Fool

Fri, 10/22/21 - 12:18 pm

Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed

Fierce Biotech

Fri, 10/22/21 - 11:26 am

cervical cancer

Pages